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Abstract
Background: N-arachidonoyl glycine (NAGly) is an endogenous signaling lipid with a wide variety of
biological activity whose biosynthesis is poorly understood. Two primary biosynthetic pathways have been
proposed. One suggests that NAGly is formed via an enzymatically regulated conjugation of arachidonic
acid (AA) and glycine. The other suggests that NAGly is an oxidative metabolite of the endogenous
cannabinoid, anandamide (AEA), through an alcohol dehydrogenase. Here using both in vitro and in vivo
assays measuring metabolites with LC/MS/MS we test the hypothesis that both pathways are present in
mammalian cells.
Results:  The metabolic products of deuterium-labeled AEA, D4AEA (deuterium on ethanolamine),
indicated that NAGly is formed by the oxidation of the ethanolamine creating a D2NAGly product in both
RAW 264.7 and C6 glioma cells. Significantly, D4AEA produced a D0NAGly product only in C6 glioma cells
suggesting that the hydrolysis of AEA yielded AA that was used preferentially in a conjugation reaction.
Addition of the fatty acid amide (FAAH) inhibitor URB 597 blocked the production of D0NAGly in these
cells. Incubation with D8AA in C6 glioma cells likewise produced D8NAGly; however, with significantly
less efficacy leading to the hypothesis that FAAH-initiated AEA-released AA conjugation with glycine
predominates in these cells. Furthermore, the levels of AEA in the brain were significantly increased,
whereas those of NAGly were significantly decreased after systemic injection of URB 597 in rats and in
FAAH KO mice further supporting a role for FAAH in endogenous NAGly biosynthesis. Incubations of
NAGly and recombinant FAAH demonstrated that NAGly is a significantly less efficacious substrate for
FAAH with only ~50% hydrolysis at 30 minutes compared to 100% hydrolysis of AEA. Co-incubations of
AEA and glycine with recombinant FAAH did not, however, produce NAGly.
Conclusion: These data support the hypothesis that the signaling lipid NAGly is a metabolic product of
AEA by both oxidative metabolism of the AEA ethanolamine moiety and through the conjugation of glycine
to AA that is released during AEA hydrolysis by FAAH.
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Background
N-arachidonoyl glycine (NAGly) was synthesized as part
of a structure activity relationship study of the endocan-
nabinoid anandamide (N-arachidonoyl ethanolamine;
AEA; Fig. 1A) differing from AEA by the oxidation state of
the carbon beta to the amido nitrogen (Fig. 1B); a modifi-
cation that drastically reduces its activity at both cannabi-
noid receptors [1]. Nevertheless, NAGly produces
antinociceptive and anti-inflammatory effects in mice and
rats [2-5]. These findings gained physiological relevance
when Huang et al. [3] demonstrated that NAGly is formed
in numerous mammalian tissues including the brain.
Subsequent studies by Kohno and colleagues [6] found
that low concentrations (EC50 ~20 nM) of NAGly activate
GPR18, an orphan G protein-coupled receptor. Consist-
ent with the anti-inflammatory effects of NAGly, GPR18 is
highly expressed in peripheral blood leukocytes and sev-
eral hematopoietic cell lines. In pancreatic beta cells,
NAGly caused intracellular calcium mobilization and
insulin release [7]. NAGly inhibited the glycine trans-
porter, GLYT2a through direct, non-competitive interac-
tions [8] and more recently was reported as a partial
agonist of Gq/11-coupled GPR92 receptors [9]. These data
support the hypothesis that NAGly is an endogenous sig-
naling molecule with multiple biological activities.
The biosynthesis and regulation of NAGly are only par-
tially understood. Unlike 2-arachidonoyl glycerol and
AEA, the biosynthesis of NAGly cannot logically be
derived from phospholipid biochemistry. Two primary
pathways for the biosynthesis of NAGly, have been pro-
posed: 1) conjugation of arachidonic acid and glycine
[2,3,10] and 2) oxygenation of AEA via the sequential
enzymatic reaction of alcohol dehydrogenase (ADH) and
aldehyde dehydrogenase [2,11].
Huang et al. [3] proposed that NAGly is synthesized by
the condensation of arachidonic acid (AA) with glycine
based upon the formation of deuterated NAGly following
incubations of brain membranes with deuterated AA and
deuterated glycine. McCue and colleagues [10] demon-
strated that NAGly is formed via cytochrome C acting on
arachidonoyl CoA and glycine in support of this conjuga-
tion pathway. Fatty acid amide hydrolase (FAAH), the pri-
mary hydrolyzing enzyme of AEA and other N-acyl
amides [12], could potentially be involved in this reaction
by acting in the biosynthetic pathway. In addition to
being a hydrolytic enzyme, FAAH was suggested to play a
role in the conjugation pathway of the biosynthesis of
AEA from AA and ethanolamine [13] and was recently
reported to participate in the synthesis of N-arachidonoyl
4-aminophenol (AM404) by conjugation of AA to exoge-
nously administered p-acetamidophenol [14]. NAGly
inhibited the hydrolysis of AEA by FAAH [3,15] indicating
that it likely interacts with FAAH, presumably as a com-
petitive substrate, though this interaction has not been
fully examined.
An alternative pathway was proposed by Burstein et al. [2]
who speculated that NAGly is produced by the oxidation
of the ethanolamine in AEA, most likely through an ADH.
Recent evidence using in vitro studies with human ADH
confirmed this hypothesis by demonstrating that AEA is
the precursor to NAGly through an aldehyde intermedi-
ate, N-arachidonoyl glycinal, which was synthesized and
measured throughout the reaction [11]. These experi-
ments show that after the reaction proceeds through to
the carboxylic acid it cannot be then formed into the alde-
hyde supporting the hypothesis that AEA is a precursor for
NAGly via ADH and further showing that the reaction
cannot proceed in the opposite direction.
Structures of AEA and NAGly Figure 1
Structures of AEA and NAGly. A) the endocannabinoid, N-arachidonoyl ethanolamine (anandamide; AEA) and B) the 
related signaling lipid, N-arachidonoyl glycine (NAGly); C) deuterium-labeled AEA with eight deuteriums on the arachidonic 
acid moiety; D) deuterium-labeled NAGly with eight deuteriums on the arachidonic acid moiety; E) deuterium-labeled AEA 
with four deuteriums on the ethanolamine moiety; F) deuterium-labeled NAGly with 2 deuteriums on the glycine moiety.
N
H
O
OH
N-arachidonoyl ethanolamine 
(Anandamide; AEA)
O
N
H
OH
O
N-arachidonoyl glycine 
(NAGly)
N
H
O
OH
DD DD
DD D D
D8- AEA
N
H
O DD DD
DD D D
O
D8- NAGly
N
H
O
OH
D
D D
D
D4- AEA
N
H
O
D D
OH
O
D2- NAGly
A
B
C
D
E
F
OHBMC Biochemistry 2009, 10:14 http://www.biomedcentral.com/1471-2091/10/14
Page 3 of 11
(page number not for citation purposes)
The potent actions of NAGly in a number of biological
systems magnify the need to better understand its biosyn-
thesis. Here using both in vitro and in vivo biochemical
assays and measuring metabolites with LC/MS/MS we
show that AEA serves as a precursor to NAGly by both oxi-
dative metabolism of the ethanolamine moiety and
through an additional conjugation pathway involving
FAAH activity.
Results
Oxidative Metabolism of deuterium-labeled AEA in RAW 
264.7 cells produces deuterium-labeled NAGly
Incubation of deuterium-labeled AEA, (D8AEA, deute-
rium labeled on the arachidonic acid chain; Fig 1C) with
RAW 264.7 murine macrophage-like cells resulted in the
production of deuterium-labeled NAGly (D8NAGly, deu-
terium labeled on the arachidonic acid chain; Fig 1D).
This was demonstrated by the isolation and measurement
of a product that has the exact retention-time and parent
mass/fragment pairing as synthetic D8NAGly (368.3/74.2;
Fig 2). Incubation of RAW 264.7 with D8NAGly did not
result in the production of a compound with the chroma-
tographic or mass spectrometric properties of D8AEA, nor
did incubation of D8AA produce either D8AEA or
D8NAGly  (data not shown). Because D8AA incubation
alone did not produce D8NAGly, this suggested that con-
jugation of D8AA to glycine was not the biosynthetic path-
way in this cell type. Furthermore, pre-incubation of RAW
264.7 cells with the FAAH inhibitor URB 597 for one hour
followed by incubation with D8AEA did not block the
production of D8NAGly. Therefore, we hypothesized that
the conversion was on the ethanolamine moiety in AEA to
form the glycine as was previously suggested [2,11].
To test this hypothesis, the same series of incubations
were performed using D4AEA (Fig. 1E), with the reasoning
that the actions of an ADH on the D4ethanolamine moi-
ety would yield a glycine with two deuterium atoms and
would, therefore, produce D2NAGly (Fig. 1F). Incubation
of D4AEA with RAW 264.7 cells yielded a product that
matched the characteristics of the proposed D2NAGly
(Figs. 3, 4). Chromatographic matches using HPLC/MS/
MS showed that a molecule with the parent mass of the
predicted D2NAGly (363.2 in negative ion mode) and a
fragment that was 2 atomic mass units (amu) greater than
the glycine fragment (76.1 and 74.1 respectively; Fig. 3A)
had the identical retention time as the non-deuterated
(D0NAGly) standard (Fig. 3B, C).
Product ion scans in positive ion mode (used to facilitate
the generation of more fragments) established that the
fragmentation pattern of non-deuterated AEA (D0AEA;
Fig. 4A) and the deuterium-labeled AEA synthesized here,
D4AEA (Fig. 4B), are identical with the exception of the
parent mass increasing by 4 amu from [348.1]+ to [352.3]+
Chromatograms of the tandem mass spectrometric (MS)  method for deuterium-labeled NAGly (D8NAGly) in which  the parent mass in negative mode [368.3]- is paired fragment  mass of glycine [74.0]- Figure 2
Chromatograms of the tandem mass spectrometric 
(MS) method for deuterium-labeled NAGly 
(D8NAGly) in which the parent mass in negative 
mode [368.3]- is paired fragment mass of glycine 
[74.0]-. A) Chromatogram of an MS scan for the 368.3/74 
pair from RAW 267.4 cell extracts that were incubated with 
deuterium-labeled anandamide. B) Chromatogram of a scan 
for the 368.3/74 pair with the synthesized D8NAGly standard 
(std). C) Overlay of the two independent scans.
0.0E+00
4.0E+03
8.0E+03
1.2E+04
1.6E+04
2.0E+04
2.5 2.7 2.9 3.1 3.3 3.5 3.7 3.9
Time (minutes)
I
n
t
e
n
s
i
t
y
 
(
c
p
s
)
0.0E+00
4.0E+03
8.0E+03
1.2E+04
1.6E+04
2.0E+04
2 . 52 . 72 . 93 . 13 . 33 . 53 . 73 . 9
I
n
t
e
n
s
i
t
y
 
(
c
p
s
)
0.0E+00
4.0E+03
8.0E+03
1.2E+04
1.6E+04
2.0E+04
2.5 2.7 2.9 3.1 3.3 3.5 3.7 3.9
I
n
t
e
n
s
i
t
y
 
(
c
p
s
)
D8NAGly from 
cell extract
D8NAGly 
standard
Overlay of 
extract and 
std
A
B
CBMC Biochemistry 2009, 10:14 http://www.biomedcentral.com/1471-2091/10/14
Page 4 of 11
(page number not for citation purposes)
and ethanolamine fragment from [62.2]+  and [66.2]+
respectively. Likewise, positive ion scans of NAGly stand-
ard (Fig. 4C) are identical to the molecule produced after
D4AEA incubation with the predicted addition of 2 amu
on the parent mass [362.2]+ and [364.4]+ respectively and
glycine fragments [76.1]+  and [78.1]+  respectively (Fig
4D). Major product ions (287, 269, 245, and 203 m/z),
which are associated with the fragmentation of AA, were
likewise the same in each of the four scans (Fig 4A–D).
These findings provide further evidence that NAGly is pro-
duced via an ADH from AEA in RAW 264.7 cells by activ-
ity on the ethanolamine moiety rather than cleavage to AA
which is subsequently conjugated with glycine.
The Role of FAAH in the Biosynthesis of Deuterium-
labeled-NAGly from Deuterium-labeled AEA in C6 glioma 
cells
FAAH plays a role in the biosynthesis of N-arachidonyl-p-
aminophenol following treatment of rats with acetami-
nophen [14]. Therefore, we hypothesized that FAAH may
catalyze the biosynthesis of NAGly in C6 glioma cells, a
murine cell line that exhibits robust FAAH activity
[16,17]. D8AEA and D4AEA were incubated with C6 gli-
oma cells using the treatment protocols described above
for RAW 264.7 cells. Compounds matching the retention
times and mass spectrometric properties of both D8NAGly
and D2NAGly were present in the respective cell extracts.
Unlike the RAW 264.7 cells, C6 glioma cells also pro-
duced excess D0NAGly after incubation with D4AEA (Fig
5A). The production of D0NAGly was prevented by pre-
incubation with the FAAH inhibitor, URB 597 (Fig. 5B),
however, like with the RAW 264.7 cells, D2NAGly was still
produced (Fig 5B).
In contrast to RAW 264.7 cells, D8AA incubated with C6
glioma cells yielded D8NAGly, however, this product was
not blocked by the addition of URB 597 (Fig. 6). Further-
more, a comparison of D8AA versus D4AEA indicated that
mole-for-mole AEA is a significantly better substrate for
the biosynthesis of NAGly in C6 glioma cells than AA (Fig
6). Significantly, blocking FAAH-dependent production
of NAGly with URB 597 produced an increase in the
amount of D2NAGly in these cells (Fig 6). Indeed, the
shunting of substrate to the ADH pathway was very effi-
cient, evidenced by the observation that the total produc-
tion of NAGly was the same with and without URB 597
(Fig. 6).
Brain levels of AEA and NAGly after URB 597 injections in 
rats and in FAAH knockout (KO) and wild-type (WT) mice
After examining the biosynthesis of NAGly in a FAAH-rich
in-vitro cellular model (C6 glioma), we sought to deter-
mine whether FAAH-dependent biosynthesis of NAGly
occurs also in vivo. We examined the levels of AEA and
NAGly in brains of rats treated with URB597 or vehicle as
Chromatograms of the tandem mass spectrometric (MS)  method for deuterium-labeled N-arachidonoyl glycine  (D2NAGly) in which the parent mass in negative mode  [362.3]- is paired fragment mass of deuterium-labeled glycine  [76.0]- or the non-deuterium-labeled N-arachidonoyl glycine  (D0NAGly) that has a parent mass in negative ion mode of  [360.3]- and a paired fragment mass of glycine [74.0]- Figure 3
Chromatograms of the tandem mass spectrometric 
(MS) method for deuterium-labeled N-arachidonoyl 
glycine (D2NAGly) in which the parent mass in nega-
tive mode [362.3]- is paired fragment mass of deute-
rium-labeled glycine [76.0]- or the non-deuterium-
labeled N-arachidonoyl glycine (D0NAGly) that has a 
parent mass in negative ion mode of [360.3]- and a 
paired fragment mass of glycine [74.0]-. A) Chromato-
gram of an MS scan for the 362.3/76 pair from RAW 267.4 
cell extracts that were incubated with deuterium-labeled 
anandamide (D4AEA). B) Chromatogram of the MS scan for 
the 360.3/74 pair with the synthesized D0NAGly standard 
(std). C) Overlay of the two independent scans.
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well as in FAAH KO and WT mice. The levels of AEA in rat
whole brain significantly increased 2 hours after systemic
injection of URB 597 (0.3 mg/kg) compared to vehicle
controls (Fig 7A). In contrast, levels of NAGly significantly
decreased (Fig 7A). The same pattern was shown in the
levels of AEA and NAGly in FAAH KO and WT mice: AEA
levels were significantly higher in FAAH KO mice,
whereas, NAGly levels were significantly lower (Fig. 7B).
NAGly hydrolysis by recombinant FAAH
The evidence that NAGly levels were significantly
decreased with FAAH inhibition and in FAAH KO mice
led us to test the hypothesis that: 1) FAAH is acting as a
biosynthetic enzyme with AEA and glycine as precursors
and 2) FAAH has a low efficacy for NAGly. If FAAH is
highly efficacious for producing robust levels of NAGly
hydrolysis, then it is unlikely to play a role in its biosyn-
thesis. Conversely, if AEA is converted to NAGly during
hydrolysis in the presence of glycine, then FAAH would be
a candidate enzyme for NAGly biosynthesis. Our results
show that when recombinant FAAH was incubated with
AEA and glycine, AEA was measured via HPLC/MS/MS
and was shown to be rapidly hydrolyzed as expected (Fig
8). At 5 minutes ~60% of all AEA was hydrolyzed and by
15 minutes over 95%. At 30 minutes there was almost no
detectable AEA present in the solution. Conversely, at 5
minutes less than 20% of NAGly was hydrolyzed and at
30 minutes there was still over 45% of NAGly still left in
the solution. There was no detectable NAGly produced in
incubations of AEA, glycine and recombinant FAAH indi-
cating that FAAH is not a direct biosynthetic enzyme in
the recombinant form.
Mass spectrometric product ion scans of synthesized standards and RAW 264.7 lipid extracts Figure 4
Mass spectrometric product ion scans of synthesized standards and RAW 264.7 lipid extracts. The numbers 
above the peaks are the calculated centroid mass. A) Positive ion mode product ion scan of the mass [348.3]+ of the synthe-
sized standard of non-deuterium labeled N-arachidonoyl ethanolamine (D0AEA). B) Positive ion mode product ion scans of the 
mass [352.3]+ of the synthesized standard of deuterium-labeled AEA (D4AEA). C) Positive ion mode product ion scan of the 
mass [362.3]+ of the synthesized standard of non-deuterium labeled NAGly (D0NAGly). D) Positive ion mode product ion scan 
of the mass [364.3]+ of the RAW 264.7 cell extract that was incubated with D4AEA.
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Discussion
The data presented here supports the hypothesis that the
endogenous cannabinoid AEA acts as a precursor in the
biosynthesis pathways of the signaling lipid NAGly. One
pathway is a FAAH-dependent conjugation of glycine to
AEA-released AA and the second is by oxidation of the eth-
anolamine moiety in AEA, likely by an ADH (Fig. 9).
The conjugation of AA with glycine to form NAGly dem-
onstrated by Huang and colleagues [3] was confirmed
here in the incubation with C6 glioma cells. The previous
assay was performed with brain membranes and is more
comparable to the brain-derived C6 glioma cells than the
macrophage RAW 264.7 cell line. As shown here, AEA had
a 4-fold greater efficacy as a substrate than AA in C6 gli-
oma cells and the production of NAGly by conjugation of
AA and glycine was not blocked by URB 597. Therefore,
the present data suggest that AEA is a substrate for NAGly
biosynthesis through the URB 597-sensitive pathway in
C6 glioma cells and brain. Through this pathway, AEA
must undergo hydrolysis by FAAH to be a substrate for
NAGly biosynthesis via conjugation.
Previously, we demonstrated that incubation of D8AEA in
a neuronal cell line (F-11) resulted in accumulation of
D8AEA in lipid rafts while its metabolite D8AA was found
mostly in non-lipid raft fractions [18]. It is possible that
the trafficking of AEA from specialized membrane com-
partments such as lipid rafts to compartments rich in
FAAH [19] may position the AA precursor in proximity to
additional enzymes that are involved in the conjugation
reaction to glycine. In essence, this would make the ara-
chidonic acid in AEA more bio-available to form NAGly.
Recently, McHue and colleagues [10] proposed that cyto-
chrome c catalyzes the synthesis of NAGly from arachido-
noyl CoA and glycine in the presence of hydrogen
peroxide suggesting yet another conjugation pathway for
the production of NAGly. These enzymes and FAAH are
present in mitochondrial membranes, which may be the
site of NAGly biosynthesis.
The conversion of AEA to NAGly through an ADH path-
way in both RAW 264.7 macrophage and C6 glioma cell
lines suggests a more ubiquitous biosynthesis reaction.
Given that there are multiple members of the protein fam-
ily of ADHs that act with different affinity to different sub-
strates [20] it would also not be surprising that the level of
NAGly production would be different with different cell
types through this pathway.
We observed that incubation of D8NAGly with RAW
264.7 and C6 glioma cells did not lead to the production
D8AEA. This finding is at variance with the report by
Burstein et al. [21] in which incubation of NAGly with
RAW 264.7 cells yielded increased levels of AEA. In the
present study we used 5 cm2 flasks for each assay which
was an amount of cells that fell below the limit to detect
endogenous AEA. In addition, the concentration of AEA
in the incubations was 10-times less than in the earlier
study. In light of the data presented here Burstein et al.'s
result [21] may represent a case where NAGly at higher
concentrations may be activating a pathway for AEA pro-
duction or sufficiently blocking its enzymatic hydrolysis
to cause a build-up of native AEA and not acting as a sub-
strate for AEA synthesis.
Chromatograms of lipid extracts of C6 Glioma of the tandem  mass spectrometric (MS) methods for both deuterium- labeled NAGly (D2NAGly) in which the parent mass in nega- tive mode [362.3]- is paired fragment mass of deuterium- labeled glycine [76.0]- and the non-deuterium-labeled N-ara- chidonoyl glycine (D0NAGly) that has a parent mass in nega- tive ion mode of [360.3]- and a paired fragment mass of  glycine [74.0]- Figure 5
Chromatograms of lipid extracts of C6 Glioma of the 
tandem mass spectrometric (MS) methods for both 
deuterium-labeled NAGly (D2NAGly) in which the 
parent mass in negative mode [362.3]- is paired frag-
ment mass of deuterium-labeled glycine [76.0]- and 
the non-deuterium-labeled N-arachidonoyl glycine 
(D0NAGly) that has a parent mass in negative ion 
mode of [360.3]- and a paired fragment mass of gly-
cine [74.0]-. A) Chromatogram of MS scans for D2NAGly 
and D0NAGly from the lipid extract of C6 Glioma cells that 
were incubated with DMSO followed by D4AEA. B) Chroma-
togram of MS scans for D2NAGly and D0NAGly from the 
lipid extract of C6 Glioma cells that were incubated with 1 
μM URB 597 followed by D4AEA.
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That the levels of NAGly were dramatically decreased in
brain after URB 597 and in the FAAH KO mice suggests
that the compensatory NAGly production shown in the
C6 glioma cells may be an acute phenomenon specific for
these cells. If NAGly production were driven by ADH in
the brain then the excess AEA generated by URB 597
should have produced an increase in NAGly. The lack of
increase in this experiment and the FAAH KO mice sug-
gests that the brain-derived NAGly is primarily through
the FAAH-dependent conjugation biosynthesis pathway.
Finally, the evidence that recombinant FAAH has a signif-
icantly lower efficacy for NAGly hydrolysis than AEA sug-
gests that it would not be readily hydrolyzed in an enzyme
complex including FAAH permitting time for production
and trafficking of the signaling molecule to its site of
action, which is likely to be at plasma membrane recep-
tors.
Conclusion
Growing evidence supports a mechanism for non-CB1,
non-CB2 activity of AEA [22-24]. The hypotheses gener-
ated from those studies were that AEA is acting on a sepa-
rate receptor or receptors or through metabolites of AEA
[24]. Here, we provide evidence that AEA is metabolized
into the signaling lipid NAGly that activates GPR18 [6]
and GPR92 [9] suggesting the hypothesis that non-CB
receptor effects of AEA are potentially through this bioac-
tive metabolite.
Comparison of NAGly production in C6 glioma cells after incubation with deuterium-labeled arachidonic acid (D8AA) or eth- anolamine moiety deuterium-labeled AEA (D4AEA) Figure 6
Comparison of NAGly production in C6 glioma cells after incubation with deuterium-labeled arachidonic acid 
(D8AA) or ethanolamine moiety deuterium-labeled AEA (D4AEA). The products measured were arachidonoyl chain 
deuterium-labeled NAGly (D8NG); non-deuterium-labeled NAGly (D0NG); and glycine moiety deuterium-labeled NAGly 
(D2NG). + denotes an addition of the compound to the cell media for 1 hour before lipid extraction. -denotes compounds that 
were not present during the incubation. # p ≤ 0.05 compared to levels of D8NG in D8AA treatment group; * p ≤ 0.05 com-
pared to levels of D2NG in D4AEA+ URB 597 treatment group; n = 6–8 per group.
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Methods
Subjects
Twelve male (300–450 g) Sprague-Dawley (Harlan, Indi-
anapolis, IN) rats were used. We also used brain tissue
from six FAAH WT and six FAAH KO mice, which were lit-
termates from the thirteenth generation offspring from
intercrosses of 129SvJ-C57BL/6 FAAH (±) mice [25]. All
protocols were approved by the Indiana University Insti-
tutional Animal Care and Use Committee.
Cell Culture
The RAW 267.4 and C6 glioma cell lines were purchased
from ATCC (Manassas, VA). Both cell lines were cultured
in DMEM (Mediatech, VA) with 10% fetal bovine serum
(Hyclone, Logan, UT) and 1% penicillin-streptomycin
(Gibco-Invitrogen, Carlsbad, CA).
Drugs and reagents
HPLC-grade methanol and acetonitrile used for mass
spectrometric studies were purchased from VWR interna-
tional (Plainview, NY). HPLC grade water, mass spec-
trometry/HPLC grade acetic acid, formic acid, and
ammonium acetate were purchased from Sigma-Aldrich
(St. Louis, MO). N- [2H8]arachidonoyl glycine
(D8NAGly), N- [2H8]arachidonoyl ethanolamine, D8AEA,
and [2H8] arachidonic acid (D8AA) were purchased from
Cayman Chemical (Ann Arbor, MI). URB 597 was pur-
chased from BIOMOL International (Plymouth Meeting,
PA). Arachidonic acid was purchased from Nu-Chek Prep
(Elysian, MN). Ethanol-1,1,2,2-d4-amine was purchased
from CDN Isotopes Inc. (Pointe-Claire, Quebec).
Synthesis of deuterium-labeled N-arachidonoyl 
ethanolamine (D4-AEA)
D4AEA was synthesized as previously described with the
exception that the ethanolamine was deuterium labeled
instead of the arachidonic acid [26].
Characterization of metabolites of D8AEA and D4AEA in 
cell culture systems
RAW 264.7 and C6 glioma cell lines were used at 70%
confluence. Cells were washed twice with dPBS then
either 1 μM of either D8AEA, D4AEA, D8AA, D8NAGly or
vehicle, DMSO (10 μl) were added to serum-free media
and incubated for 1 hour. In experiments in which the
FAAH inhibitor URB 597 was used, the cells were first
incubated with 1 μM URB 597 or DMSO vehicle (10 μl)
in serum-free media for one hour prior to D8AEA or
D4AEA that was added directly to this media. Then, equal
volumes of methanol were added to the flasks; cells were
scraped, aspirated, and centrifuged at 2000 × g for 15 min
at 24°C. Supernatants were collected and HPLC grade
water was added to make a 30% organic solution. Lipids
were partially purified on C18 solid phase extraction col-
umns as previously described [27]. In brief, each 500 mg
column was conditioned with 5 ml methanol and 2.5 ml
water followed by loading of the water/supernatant solu-
tion. Columns were then washed with 2 ml water and 1.5
ml 55% methanol. Compounds were eluted with 1.5 ml
methanol. Eluants were vortexed at maximum speed prior
to mass spectrometric analysis.
Rapid separation of analytes was obtained using 10 μl
injections (Agilent 1100 series autosampler, Wilmington,
DE) onto a Zorbax eclipse XDB 2.1 × 50 mm reversed
phase column. Gradient elution (200 μl/min) was formed
under pressure on a pair of Shimadzu (Columbia, Mary-
land) 10AdVP pumps. Mass spectrometric analysis was
performed with an Applied Biosystems/MDS Sciex (Foster
City, CA) API 3000 triple quadrupole mass spectrometer
equipped with an electrospray ionization source. Levels of
each compound were analyzed by multiple reactions
monitoring (MRM) on the LC/MS/MS system. Mass spec-
trometric conditions were optimized for each compound
using direct flow injection of synthetic standards of each
Production of N-arachidonoyl ethanolamine (AEA) and N- arachidonoyl glycine (NAGly) in whole brain Figure 7
Production of N-arachidonoyl ethanolamine (AEA) 
and N-arachidonoyl glycine (NAGly) in whole brain. 
A) Levels of AEA and NAGly in rat whole brain two hours 
after vehicle (white bar) or 3 μg/kg URB 597 (black bar). * p 
≤ 0.05 B) Levels of AEA and NAGly in mouse whole brain of 
WT (white bar) or FAAH KO (black bar). * p ≤ 0.05.
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compound. Product ion scans were performed with iden-
tical chromatographic conditions as the MRM scans with
identical ionization and collision energy.
Eluants were tested for levels of D8AEA, D4AEA, D8NAGly,
D2NAGly, (Fig. 1) and D8AA using MRM tandem mass
spectrometric methods with parent and fragment ions as
follows: in positive ion mode, AEA 348.3 → 62.3, D8AEA
356.3 → 62.3 and D4AEA 352.3 → 66.3; in negative ion
mode, NAGly 360.2 → 76.2, D8NAGly 368.2 → 76.2,
D2NAGly 362.2 → 78.2, and D8AA 311.5 → 267.3. Prod-
uct ion scans were performed for D0NAGly and D2NAGly
using the API 3000 scanning in positive ion mode for the
products of 362.2 and 364.2 respectively.
Quantification of tissue levels of AEA and NAGly
Each of the analytes was extracted and quantified using
methods reported [27]. In brief, whole brains were dis-
sected and flash-frozen in liquid nitrogen prior to lipid
extraction, at which time twenty volumes of ice-cold
Comparison of hydrolysis rates of N-arachidonoyl eth- anolamine (AEA) and N-arachidonoyl glycine (NAGly) via  recombinant FAAH Figure 8
Comparison of hydrolysis rates of N-arachidonoyl 
ethanolamine (AEA) and N-arachidonoyl glycine 
(NAGly) via recombinant FAAH. n = 4–6 per time 
point. Time points (minutes): 1, 3, 5, 9, 15, 30.
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Two pathways for N-arachidonoyl glycine (NAGly) biosynthesis from N-arachidonoyl ethanolamine (AEA) Figure 9
Two pathways for N-arachidonoyl glycine (NAGly) biosynthesis from N-arachidonoyl ethanolamine (AEA).
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methanol and 100 pmol D8NAGly (internal standard)
were added to the methanol-tissue sample. The samples
were maintained on ice and homogenized via polytron
for 2 min and centrifuged for 20 min at 40,000 × g at
24°C. Supernatants were transferred to polypropylene 50
ml centrifuge tubes (VWR, Plainview, NY) and HPLC
grade water was added to each sample to create a 70:30
(water:supernatant) mixture. Partial purification on C18
solid phase extraction and mass spectrometric analyses
were identical to that described above.
Effects of inhibition of FAAH on brain levels of AEA and 
NAGly
Animals were injected with either URB 597 (0.3 mg/kg, in
1% DMSO, i.p.) or vehicle. After two hours animals were
decapitated and brains were dissected and flash-frozen in
liquid nitrogen, extracted, purified and analyzed as
described above.
Analysis of brain extracts from FAAH KO and WT mice
FAAH KO and WT mice were sacrificed when they were 6
weeks old. The brains were dissected and stored at -80°C
until used. Lipid extraction, partial purification, and
quantitation were performed using the methods
described above.
Recombinant FAAH cell-free assay
To determine the rates of AEA and NAGly hydrolysis a
solution of ethanol and compound (400 μM, 10 μl) was
added to a solution of recombinant FAAH protein (10 μl,
1.3 μg/μl in 20 mM HEPES (pH 7.8), 150 mM NaCl, 10%
glycerol, 1% Triton X-100) in buffer (Tris/EDTA, 380 μl,
pH 9) at room temperature. A 40 μl aliquot of the reaction
mixture was taken at appropriate time points and
quenched with 1 ml of MeOH. To control for loss of AEA
and NAGly to the sides of the tube and into micelles in the
aqueous buffer, equal numbers of controls were run at the
same time without FAAH. 1 μl of the quenched solution
from each (FAAH incubations and controls) was analyzed
by LC/MS/MS mass spectrometry as discussed above.
Hydrolysis rates were determined by the average values of
the analyte measured from the FAAH incubations sub-
tracted from the average values of the controls (incuba-
tions with buffer and no FAAH) at each time point.
Data Analysis
Mass spectrometric quantitation
The quantitation of analytes was achieved using Analyst
software (Applied Biosystems-MDS Sciex; Framingham
MA), which quantifies the amount of analyte in the sam-
ple based upon a power fit of a linear regression of known
concentrations of synthetic standards. Those data were
then analyzed as vehicle verses drug in the case of the URB
597 and as FAAH KO verses WT. Statistical differences
were determined using ANOVA with post-hoc Fisher's
LSD using a 95% confidence interval for the mean (SPSS
software, Chicago, IL). Data are presented as mean ±
standard error of the mean where p ≤ 0.05 was considered
statistically significant
List of abbreviations
(D8NAGly): N- [2H8]arachidonoyl glycine; (D8AEA): N-
[2H8]arachidonoyl ethanolamine; (D8AA): [2H8] arachi-
donic acid; (D2NAGly):  N- [2H2]arachidonoyl glycine;
(D4AEA):  N- [2H4]arachidonoyl ethanolamine; (AEA):
arachidonoyl ethanolamide; (NAGly): N-arachidonoyl
glycine; (AA): arachidonic acid; (FAAH): fatty acid amide
hydrolase.
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